Accordingly, targeting T-cell-exclusion pathways in malignant cells induces T cell chemokines, increases intratumoral T cell accumulation, and potentiates tumor responses to PD-(L)1 blockade (10–13). This evidence concerns the gene CD274 and neoplasm.